The present work aims to give a contribution to the understanding of the highly infectious pandemic caused by the COVID-19 in the African continent. The study focuses on the modelling and the forecasting of COVID-19 spread in the most affected African continent, namely: Morocco, Algeria, Tunisia, Egypt and South Africa and for the sake of comparison two of the most affected European country are also considered, namely: France and Italy. To this end, an epidemiological SEIQRDP model is presented, which is an adaptation of the classic SIR model widely used in mathematical epidemiology. In order to better coincide with the preventive measures taken by the governments to deal with the spread of COVID-19, this model considers the quarantine. For the identification of the models parameters, official data of the pandemic up to August 1st, 2020 are considered. The results show that the number of infections due to the use of quarantine is expected to be very low provided the isolation is effective. However, it is increasing in some countries with the early lifting of containment. Finally, the information provided by the SEIQRDP model could help to establish a realistic assessment of the short-term pandemic situation. Moreover, this will help maintain the most appropriate and necessary public health measures after the lockdown lifting.
Competing Interest Statement
The authors have declared no competing interest.
There are no funding supported in this work
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.